Health-related quality of life in Egyptian children and adolescents with hemophilia A

Pediatric Hematology and Oncology

Volumn 28, Issue 3, 2011, Pages 222-229

  Tantawy, Azza A G ^a   MacKensen, Sylvia Von ^b   El Laboudy, Mohammed A M ^a   Labib, Jonair H ^a   Moftah, Faten ^c   El Telbany, Manal A S ^a   Mansour, Wesam A A ^d  

^a AIN SHAMS UNIVERSITY   (Egypt)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c National Blood Bank   (Egypt)

^d Department of Research and Development   (Egypt)

Author keywords

FVIII inhibitors; Haemo QoL; hemophilia

Indexed keywords

BLOOD CLOTTING FACTOR 8 INHIBITOR;

ACADEMIC ACHIEVEMENT; ADOLESCENT; ARTICLE; CHILD; CLINICAL FEATURE; EGYPT; FAMILY; FEASIBILITY STUDY; FRIEND; GROUPS BY AGE; HAEMO QOL QUESTIONNAIRE; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; PHYSICAL ACTIVITY; PRESCHOOL CHILD; QUALITY OF LIFE; QUESTIONNAIRE; SCHOOL CHILD; SCORING SYSTEM; SOCIAL SUPPORT; SPORT;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DELIVERY OF HEALTH CARE; EGYPT; FEASIBILITY STUDIES; FEMALE; HEALTH STATUS; HEMOPHILIA A; HUMANS; MALE; QUALITY OF LIFE; QUESTIONNAIRES;

EID: 79952500506     PISSN: 08880018     EISSN: 15210669     Source Type: Journal    
DOI: 10.3109/08880018.2010.535116     Document Type: Article

References (22)

1. Casaña P, Cabrera N, Cid AR, et al. Severe and moderate hemophilia A: identification of 38 new genetic alterations. Haematologica. 2008;93:1091-1094. (Pubitemid 351957029)
2. Konkle BA, Kessler C, Aledort L, et al. Emerging clinical concerns in the ageing haemophilia patient. Haemophilia. 2009;15:1197-1209.
3. Bullinger M. Quality of life - definition, conceptualization and implications-a methodologist's view. Theor Surg. 1991;6:143-149.
4. Bullinger M, von Mackensen S. Psycho-social determinants of quality of life in children and adolescents with haemophilia-a cross-cultural approach. Clin Psychol Psychother. 2008;15:164-172. (Pubitemid 351982891)
5. Pollak E, Mu Hlan H, Von Mackensen S, et al. The Haemo-QoL Index: developing a short measure for health-related quality of life assessment in children and adolescents with haemophilia. Haemophilia. 2006;12:384-392
6. Remor E, Young NL, von Mackensen S, et al. Disease-specific quality-of-life measurement tools for haemophilia patients. Haemophilia. 2004;10:30-34. (Pubitemid 40045416)
7. Young NL, Bradley CS, Wakefield CD, et al. How well does the Canadian haemophilia Outcomes-Kids-Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia? Pediatr Blood Cancer. 2006;47:305-311. (Pubitemid 44148048)
8. Bullinger M, von Mackensen S, Fischer K, et al. Pilot testing of the Haemo-QoL quality of life questionnaire for haemophiliac children in six European countries. Haemophilia. 2002;8:47-54. (Pubitemid 34498629)
9. Von Mackensen S, Bullinger M, the Haemo-QoL Group. Development and testing of an instrument to assess the Quality of Life of Children with Hemophilia in Europe (Haemo-QoL). Hemophilia. 2004;10:17-25. (Pubitemid 40045396)
10. Dacie JV and Lewis SM. Dacie and Lewis Practical Hematology. London: Churchill Livingstone; 2001.
11. Bullinger M, Von Mackensen S. Quality of life assessment in hemophilia. Hemophilia. 2004;10:9-16.
12. Gringeri A, von Mackensen S, Auerswald G, et al. Health status and health-related quality of life of children with haemophilia from six West European countries. Haemophilia. 2004;10:26-33. (Pubitemid 40045397)
13. El Alfy MS, Tantawy AAG, Ahmd MH, et al. Frequency of inhibitor development in severe haemophilia A children treated with cryoprecipitate and low-dose immune tolerance induction. Haemophilia. 2000;6:635-638.
14. Ettingshausen CE, Kreuz W. Recombinant versus plasma-derived products, especially those with intact VWF, regarding inhibitor development. Haemophilia. 2006;12:102-106. (Pubitemid 44741510)
15. Hay CR. The epidemiology of factor VIII inhibitors. Haemophilia. 2006;12:23-28.
16. Gouw SC, Van den Berg MH. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost. 2009;35:723-34.
17. Kitchen S, Jennings I, Preston FE, et al. Interlaboratory variation in factor VIII:C inhibitor assay results is sufficient to influence patient management: data from the UK national quality external assessment scheme for blood coagulation. Semin Thromb Hemost. 2009;35:778-785.
18. Oldenburg J, Pavlova A. Genetic risk factors for inhibitors to factors VIII and IX. Haemophilia. 2006;12:15-22. (Pubitemid 44741498)
19. Wang XF, Zhao YQ, Yang RC, et al. The prevalence of factor VIII inhibitors and genetic aspects of inhibitor development in Chinese patients with haemophilia A. Haemophilia. 2010;16:632-639.
20. Manco-Johnson M, Morrissey-harding G, Edelman-Lewis B, et al. Development and validation of a measure of disease-specific quality of life in young children with hemophilia. Hemophilia. 2004;10:34-41. (Pubitemid 38195623)
21. Bergner M. Quality of life, health status, and clinical research. Med Care. 1989;27: S148-S156.
22. Miners AH, Sabin CA, Tolley KH, et al. Assessing health-related quality-of-life in individuals with haemophilia. Haemophilia. 1999;5:378-385. (Pubitemid 30003764)